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Hereditary breast cancer is a genetically and clinically heteroge-
neous disease, and several susceptibility genes have been identi-
fied to date (Rahman and Stratton, 1998). The Breast Cancer
Linkage Consortium analysed 237 families with at least four cases
of breast cancer and any number of ovarian cancer, and estimated
that 81% of the breast–ovarian cancer families were due to
BRCA1 on 17q12–21, with most others (14%) due to BRCA2 on
13q12–13 (Ford et al, 1998). Conversely, 76% of the families with
male and female breast cancer were due to BRCA2. The largest
proportion (67%) of families due to other genes was found in
families with four or five cases of female breast cancer only.
The disease associated mutation spectrum of the BRCA1 gene
is predominantly composed of small insertions and deletions,
leading to premature translation termination (Breast Cancer
Information Core (BIC) Website, March 1999). Although these
mutations occur throughout the entire coding region, several have
been repeatedly detected in specific populations. For most of these
mutations, haplotype analyses of the carriers strongly suggested a
founder effect (Szabo and King, 1997). For the Dutch population
we have also described several founder mutations in the BRCA1
gene. For example, the 2804delAA mutation, constitutes approxi-
mately 15% of the total Dutch BRCA1 mutation spectrum (Peelen
et al, 1997). Two large genomic deletions, encompassing exons 13
and 22 respectively, were also found to be major founder muta-
tions, accounting for at least 25% of the mutations described in the
Dutch population thus far (Petrij-Bosch et al, 1997). These dele-
tions probably arose through Alu-mediated recombination, and are
difficult to detect by polymerase chain reaction (PCR)-based
mutation screening.
The mutation spectrum of BRCA2 is less well characterized
than that of BRCA1, mainly because fewer BRCA2 mutations
have been reported to date. By far the greatest majority of them are
again frame-shifting (i.e. small deletions and insertions) and non-
sense mutations, which occur in all coding exons (Breast Cancer
Information Core Website). Few major founder mutations have so
far been detected: the 999del5 mutation in the Icelandic popula-
tion, the 6174delT mutation in the Ashkenazi Jewish population,
and the 8765delAG mutation in the French-Canadian population
(Neuhausen et al, 1996, 1998; Thorlacius et al, 1996; Tonin et al,
1998). We employed the protein truncation test (PTT) to search for
mutations in exons 10 and 11 of the gene, which together comprise
59% of the coding region, in a total of 81 Dutch hereditary breast
cancer families. Furthermore, we also applied Southern analysis of
the entire coding region of BRCA2, to investigate whether large
genomic deletions, like in BRCA1, could form a significant
proportion of the Dutch mutation spectrum.
SUBJECTS AND METHODS
Family selection
Families were ascertained by the Foundation for Detection of
Hereditary Tumors in Leiden and the Family Cancer Clinic and the
Department of Clinical Genetics in Rotterdam. Medical and/or
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Summary We have analysed 81 families with a history of breast and/or ovarian cancer for the presence of germline mutations in BRCA2 with
a number of different mutation screening techniques. The protein truncation test (PTT) for exons 10 and 11 detected four different frame-
shifting mutations in six of these families. Four of the remaining 75 families had given positive linkage evidence for being due to BRCA2. In
these families the entire coding region was analysed by single-strand conformational polymorphism, leading to the detection of a non-sense
and a splice-site mutation in two of them. While these studies were in progress, Southern analysis of BRCA1 revealed that in our study-
population of 81 families, 15 families were segregating either the exon 13 or exon 22 deletion in BRCA1 (Petrij-Bosch et al (1997) Nat Genet
17: 341–345). This prompted us to examine BRCA2 in the remaining 58 families by Southern analysis, using two different restriction
enzymes. No aberrations were found in the restriction patterns. Thus, contrary to BRCA1, large genomic rearrangements within the BRCA2
gene do not represent a major mutation mechanism among Dutch breast cancer families. © 2000 Cancer Research Campaign
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The Netherlandspathological records verified cancer diagnoses, if available. The
families were selected on the following criteria: no BRCA1 muta-
tion at the time they entered the study, and at least two cases of
breast cancer diagnosed under 60, or ovarian cancer at any age.
When lod-scores had been calculated (Cornelis et al, 1995; Peelen
et al, 1996), the lod-score for BRCA1 should be lower than –0.5
and/or the lod-score for BRCA2 should be higher than 0.5.
DNA and RNA isolation
Genomic DNA was extracted from 20 ml EDTA or heparinized
blood according to a standard salting out procedure (Miller et al,
1988). Total RNA was isolated from peripheral blood lymphocytes
as described (Hogervorst et al, 1995).
Reverse transcription and PCR
First-strand cDNA synthesis and PCR were performed as described
(Hogervorst et al, 1995). The primer-pair used for PCR was as
follows: BR2-22F 5¢ TTGCGTATTGTAAGCTATTCAAAAA 3¢
and BR2-25R 5¢ GTCTATCCAAAACTTTATTGCCAGT 3¢.
PCR on genomic DNA and PTT
Five overlapping genomic DNA fragments of BRCA2 exon 11 and
one fragment of exon 10 were amplified for use in the protein trun-
cation test. Primer pairs used for amplification are listed in Table 1.
Fifty to 100 ng genomic DNA was amplified in a 25 ml reaction
volume containing buffer no. 6 (Stratagene), 5 pmol of each primer,
0.1 mM dNTP mix (final concentration), and 0.15 ml Amplitaq
(Perkin-Elmer). The samples were cycled at 94°C for 45 s, 55°C
for 1 min and 72°C for 2.5 min for 35 cycles. In vitro transcription
and translation was performed as described elsewhere using the T7
coupled reticulo lysate system (Promega) (Hogervorst et al, 1995).
Single-strand conformation polymorphism
The conditions for single-strand conformation polymorphism
(SSCP) analysis and the primers used have been described previ-
ously (Lancaster et al, 1996).
Cloning of BRCA2 cDNA-probes
Oligo-dT primed cDNA, obtained using total RNA isolated from
the breast cancer cell line MCF7, was used as template in a nested
PCR to amplify fragments of BRCA2 exon 2–9, 12–17, 18–22, and
23–27. Primer-pairs used for PCR are available upon request.
Reaction conditions and thermocycling were essentially as those
described in PCR and PTT. After Qiaquick column purification
(Qiagen), the PCR products were ligated in a pGEM-T-Easy Vector
System I (Promega) according to the suppliers protocol. One
microlitre of the ligation product was transformed in XL1-Blue
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Table 1 BRCA2 exon 10 and 11 PTT primer sequences
Primer name Sequence Product length
BR2–10Fa 5¢ GCT TTA ACA GGA TTT GGA AAA ACA TC 3¢
BR2–10R 5¢ AAA CAC AGA AGG AAT CGT CAT C 3¢ 1169
BR2–11A-Fa 5¢ GTG CAT TCT TCT GTG AAA AGA AGC 3¢
BR2–11A-R 5¢ GCA CTT CAA ATG TAC TCT TCT GC 3¢ 1517
BR2–11B-Fa 5¢ GTA AAG CAG CAT ATA AAA ATG ACT C 3¢
BR2–11B-R 5¢ TTT CAT CAC GTT CGG GTT GT 3¢ 1625
BR2–11C-Fa 5¢ GCT GCT GCC AGT AGA AAT TCT CA 3¢
BR2–11C-R 5¢ TTC GGA GAG ATG ATT TTT GTC A 3¢ 1208
BR2–11D-Fa 5¢ GAA GAA AGA GCA AAA AGT CCT GC 3¢
BR2–11D-R 5¢ AAA CTT GCT TTC CAC TTG CTG 3¢ 1244
BR2–11E-Fa 5¢ GCT TGT GGG ATT TTT AGC ACA GC 3¢
BR2–11E-R 5¢ TGG CAA CAC GAA AGG TAA AA 3¢ 932
a All forward primers carry a Kozak sequence to initiate translation: 5¢ CGC TAA TAC GAC TCA CTA
TAG GAA CAG ACC ACC ATG 3¢.
Table 2 Families carrying a BRCA2 mutation
Family Nucleotide Exon Codon Amino acid Number of Number of a priori a priori
change breast cancer ovarian cancer chance chance
cases cases BRCA1a BRCA2a
RUL059 4542delC 11 1438 stop 1447 3 – ? ?
EUR014 4708insA 11 1494 stop 1513 5 2 0.88 0.12
RUL001b 5579insA 11 1784 stop 1786 10 – 0.19 0.66
RUL103 5579insA 11 1784 stop 1786 6 2 0.88 0.12
EUR035 5579insA 11 1784 stop 1786 – 6 0.88 0.12
RUL017 5873C>A 11 1882 stop 1882 7 2 0.88 0.12
RUL024 8295T>A 18 2689 stop 2689 6 – 0.19 0.66
RUL009 9345G>A 23 3039 splice 9 1 0.69 0.19
aAccording to Ford et al (1998); bIn RUL001 breast cancer cases are the total of paternal and maternal families.competent cells using electroporation. Plasmid DNA was isolated
using a plasmid mini kit (Qiagen) and checked for the length of the
insert by EcoRI digestion. Fragments of BRCA2 exon 2–9, 12–17,
18–22 and 23–27 were amplified from the clones with internal
primers, and their identity was checked for by restriction analysis.
Probes were 32P-labelled using a Megaprime kit (Amersham).
Southern blotting
Five micrograms of genomic DNA was digested with either EcoRI
or BglII, electrophoresed, blotted, and hybridized with either of the
four BRCA2 probes as described earlier for BRCA1 (Petrij-Bosch
et al, 1997).
Sequencing
Samples showing an extra band of lower molecular weight in the
PTT were subjected to direct sequencing using M13-tailed and
biotinylated primers on a Pharmacia A.L.F. sequencer.
RESULTS
A total of 81 families were analysed for the presence of truncating
mutations in exons 10 and 11 of BRCA2, using the protein trunca-
tion test. Four different mutations were detected in six families
(Table 2). Three families, RUL001, RUL103 and EUR035, carried
the same mutation (5579insA). Analysis of the haplotypes of these
families (Neuhausen et al, 1998) suggested that they share a
common ancestor. Yet, the phenotypes of these three families
differ strikingly in terms of breast and ovarian cancer incidence.
EUR035 is an ovarian cancer-one family with six cases of ovarian
cancer. RUL103 is a typical breast-ovarian cancer family with six
breast and two ovarian cancer cases, and RUL001 is a breast
cancer-only family with ten cases of breast cancer. In EUR035 and
RUL103, carrier status for the 5579insA was proven for two breast
cancer patients and six ovarian cancer patients. Unexpectedly,
however, we found that only two breast cancer cases of RUL001
were carrying the detected mutation (ID20 and ID21), whereas the
other six cases which could be tested for the mutation were nega-
tive (Figure 1). These six cases all occur in the maternal family of
the carrier. Subsequently, we were able to show that she inherited
the mutation from her father, because we detected the mutation in
the grand-daughter of her paternal uncle. One of the six mutation-
negative cases (ID29, Figure 1) was selected for further testing,
and was negative in the PTT.
Linkage analysis was performed previously on 13 of the 81
families selected for this study. Only four of these 13 families
showed a lod-score higher than one, corresponding to a posterior
probability of being linked to BRCA2 of more than 0.80 (Peelen
et al, 1996). These four families remained negative in our PTT.
Therefore, probands from these families were subjected to SSCP
analysis of the entire BRCA2 coding region. Two of these showed
an aberrant banding pattern. Sequencing of the variants revealed
one premature stop-codon in exon 18 and a potential splice-donor
site mutation in exon 23 in families RUL024 and RUL009 respec-
tively (Table 2). The effect of the splice-site variant on mRNA-
processing was confirmed in a breast cancer patient of RUL009 by
performing reverse transcription (RT)-PCR using a forward primer
in exon 22 and a reverse primer in exon 25 of BRCA2. This
revealed an extra band of about 250 bp in addition to the expected
wild-type product of 407 bp (Figure 2). Sequence analysis of the
junction fragment revealed that 164 bp were deleted relative to the
BRCA2 mutations in Dutch families 153
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Figure 1 Breast cancer family RUL001 carrying the 5579insA mutation in BRCA2. The mutation (indicated with M) was initially found in individual 20. One of
her sisters (ID21) did carry the mutation as well, while her mother (ID8) and several of the maternal nieces do not carry the 5573insA mutation. Detection of the
5579insA mutation in the granddaughter (ID28) of the paternal uncle of the proband demonstrated the paternal origin of the mutation
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Figure 2 RT-PCR analysis of mRNA from a 9345G>A mutation carrier in
family RUL009. cDNA was amplified with a forward primer in exon 22 and a
reverse primer in exon 25 of BRCA2. Lane 1: mutation carrier, lane 2: healthy
unrelated control. The mutation carrier shows, in addition to the wild-type
fragment of 407 bp, a band of about 250 bp. Sequence analysis revealed a
deletion of the complete 164 bp of exon 23wild-type sequence, which exactly matched the complete exon 23.
The 8295T>A in exon 18 created a DdeI-site, while the 9345G>A
abolished a MspI-site. Restriction-analysis with these enzymes of
the respective PCR-products generated from probands in the
remaining study group (n = 73) did not reveal additional families
carrying either mutation.
Meanwhile, Southern analysis of BRCA1 had revealed that in
our study population of 81 families, probands of 15 families were
carriers of either the exon 13 or exon 22 deletion in BRCA1
(Petrij-Bosch et al, 1997). This prompted us to examine the entire
coding region of BRCA2 by Southern analysis as well, in the
remaining 58 families. Therefore, the genomic DNA of the youngest
breast or ovarian cancer case from each family was digested with
either EcoRI or BglII, blotted and hybridized with either of the four
cDNA probes, containing exons 2–9, 12–17, 18–22 and 23–27 of
BRCA2 respectively (Figure 3A). No alterations in the hybridiza-
tion patterns, relative to controls and predicted by the restriction-
map (Figure 3B), were found.
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Figure 3 (A) Southern blot analysis. Genomic DNA was digested with BglII (B) or EcoRI (E) and hybridized with either of the four cDNA probes containing
exons 2–9, 12–17, 18–22 and 23–27 respectively. Hybridization patterns were as expected from the restriction maps for both BglII and EcoRI. (B) The genomic
organization of BRCA2 and restriction maps of BglII (B) and EcoRI (E) as predicted by the genomic sequences from Genbank (Z74739, exons 1–24, and
Z73359, exons 25–27). Numbers refer to the size of restriction fragments (in kb) detected by the four cDNA probes, above the bar for BglII and below the bar for
EcoRI. Arrowheads indicate the presence and orientation of Alu-elementsDISCUSSION
We have performed BRCA2 mutation analysis in 81 Dutch
breast–ovarian cancer families by a combination of PTT, SSCP
and Southern blot analysis. A total of eight truncating mutations
were detected. Of the 81 families studied, 57 comply with the
criteria used by Ford et al (1998), i.e. they have at least four cases
of breast cancer and any number of ovarian cancer cases. If we
apply the prior probabilities, as estimated for each of the different
phenotype classes (Ford et al, 1998), that each family in this set is
due to BRCA1 or BRCA2, than we would predict 24 BRCA1 and
16 BRCA2 mutations to be present among them. Indeed, while the
work presented here was going on, 15 of the 81 families were iden-
tified to be due to a large genomic deletion in BRCA1 (Petrij-
Bosch et al, 1997). Our PTT for exons 10 and 11 of BRCA2 would
be able to detect ~70% of the mutations currently held in the BIC,
which would equate to 12 mutations. Thus our finding of six trun-
cating mutations in this region suggests that we are still missing a
significant proportion of BRCA2 mutations, if the BIC mutation
spectrum would apply to the Dutch population. Nevertheless, our
finding that eight out of 66 BRCA1-negative families (12%) are
BRCA2-positive, corresponds well with that of other large studies
(i.e. >25 families) in which the entire coding region of BRCA2
was investigated (Phelan et al, 1996; Ramus et al, 1997; Serova-
Sinilnikova et al, 1997; Vehmanen et al, 1997).
An obvious explanation for our results is the presence of
unknown mutations that cannot be picked up by the PTT as
described here, which is PCR-based and restricted to exons 10 and
11. The estimates of Ford et al (1998), as well as the BIC mutation
spectrum are derived from a collection of families with a broad
geographic origin and might not apply to local populations. For
example, inherited breast cancer in Iceland is almost completely
due to a single mutation in BRCA2, in contrast to what is predicted
by the BCLC (Thorlacius et al, 1996). We decided therefore to
investigate the possibility that large genomic rearrangements in
BRCA2 existed in the Dutch population, prompted by our
previous finding that two such deletions represent major founder
mutations in BRCA1 (Petrij-Bosch et al, 1997). Southern analysis
using cDNA-probes covering the entire coding region of BRCA2
of probands from 59 families did not reveal any aberrant disease-
linked restriction-patterns. This contrasts sharply with our find-
ings, and those of others (Puget et al, 1997, 1999), for BRCA1.
The genomic sequence of BRCA1 contains a relatively high
percentage of Alu-elements (41.5%, or one per 0.65 kb) (Smith et
al, 1996). These repetitive elements have been suggested to facili-
tate intragenic recombination leading to exon deletions or duplica-
tions in BRCA1 (Petrij-Bosch et al, 1997; Puget et al, 1999). The
genomic sequence of BRCA2 harbours approximately half as
many Alu-repeats as does BRCA1, but still these elements occur
on average every 1.5 kb (Genbank accessions Z74739, Z73359).
In theory, therefore, Alu-mediated BRCA2-rearrangements cannot
be excluded, but they are likely to occur less frequently. Although
no other study has as yet investigated such a large set of families
by Southern analysis, this is in accord with the fact that only two
genomic rearrangements in BRCA2 have been published so far.
One concerns an insertion of an Alu-element into exon 22, which
resulted in its alternative splicing and skipping (Miki et al, 1996).
The other is a 5 kb genomic deletion of exon 3, of which it was
unclear whether it was caused by Alu-recombination (Nordling et
al, 1998). These findings illustrate that large genomic rearrange-
ments in BRCA2 are indeed part of the mutation spectrum.
However, given that few major founder mutations have been iden-
tified in BRCA2 thus far, their role will probably remain limited.
The six mutations we found by PTT in our families were all
located between the nucleotides 3035 and 6629. This region has
been indicated as ovarian cancer cluster region (OCCR) (Gayther
et al, 1997). In families with mutations in this region, the ratio of
the number of ovarian cancer versus breast cancer cases is signifi-
cantly higher than in families with mutations outside this region.
The overall ratio of ovarian versus breast cancer was 12:24 in the
six families carrying a mutation located in the OCCR, while in the
two families with a mutation outside the OCCR it was 1:15. Of
note, of family RUL001, only the breast cancer cases contributed
by the branch of the family in which the mutation was found, were
counted. Although the number of families is small, this finding
supports the previous report of Gayther et al (1997)
Hence the majority of families studied here have remained nega-
tive for mutations in the BRCA2 gene, even though many showed a
clear predisposition to breast and/or ovarian cancer. Further work is
required to investigate other mutation mechanisms, or parts of
BRCA1 and BRCA2 that have not yet been mutation-screened in
great detail (such as the promotor region of both genes). This will
more accurately determine the mutation spectrum in Dutch breast
cancer families. Finally, the families under study here are very
heterogeneous in terms of number of cases of breast and/or ovarian
cancer per family. It is therefore conceivable that a proportion of
these families will be assigned to mutations conferring lower breast
cancer risks in genes other than BRCA1 or BRCA2, or represent
chance clustering of non-genetic cases.
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